



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Alagebrium chloride

Cat. No.:	HY-106024B
CAS No.:	341028-37-3
Molecular Formula:	C ₁₃ H ₁₄ ClNOS
Molecular Weight:	267.77
Target:	Endogenous Metabolite
Pathway:	Metabolic Enzyme/Protease
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H₂O : 50 mg/mL (186.73 mM; Need ultrasonic)

DMSO : ≥ 25 mg/mL (93.36 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	<div>Solvent</div> <div>Concentration</div>	Mass	1 mg	5 mg	10 mg
	1 mM	3.7345 mL	18.6727 mL	37.3455 mL	
	5 mM	0.7469 mL	3.7345 mL	7.4691 mL	
	10 mM	0.3735 mL	1.8673 mL	3.7345 mL	

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (373.45 mM); Clear solution; Need ultrasonic

2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (9.34 mM); Clear solution

3. Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (9.34 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Alagebrium chloride (ALT711) is an advanced glycation end product (AGE) inhibitor.
IC ₅₀ & Target	AGE ^[1]
In Vitro	Alagebrium chloride is an advanced glycation end product (AGE) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAO of obese (ZO) and diabetic (ZD) rats ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Blood pressure is not affected by treatment with Alagebrium. In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compared with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice^[1]. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intima thickness as a function of local radius is found in all groups with Alagebrium treatment. A significant increase in TGF- β expression is also found in the AAO of ZL rats treated with Alagebrium^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Cell Assay ^[2]

Human aortic endothelial cells (HAECs) are seeded on decellularized matrices derived from the abdominal aorta (AAo) of Zucker lean (ZL), obese (ZO), and diabetic (ZD) rats with or without Alagebrium (ALT-711) (20 μ g/mL in Dulbecco's PBS with 1 \times antibiotic-antimycotic). Experiments are performed when cells reach 80 to 90% confluence. Flow chambers are sealed to the HAEC monolayers via a vacuum network. Flow is driven by a Masterflex L/S peristaltic pump in a humidified chamber heated to 37°C for 4 h. Leibovitz-15 medium, supplemented with 10% FBS, endothelial BulletKit, and 1 \times antibiotic-antimycotic solution, is used as the flow medium to maintain pH in the absence of CO₂^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

RAGE apoE mice are randomized to be treated with Alagebrium (1 mg/kg/day by gavage), or no treatment (n=20/group). After 20 weeks of diabetes, mice are placed into individual metabolic cages for 24 h and urine is collected. Body weight as well as fluid and food intake are recorded. Urinary albumin excretion is estimated in urine samples by a mouse albumin enzyme-linked immunosorbent assay (ELISA) kit according to the kit protocol. Urinary and serum creatinine concentrations are measured by high-performance liquid chromatography (HPLC). Systolic blood pressure is assessed by a noninvasive tail cuff method in conscious mice at the end of the study^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Am J Transl Res. 2019 Mar 15;11(3):1569-1580.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Watson AM, et al. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. *Diabetes*. 2012 Aug;61(8):2105-13.

[2]. Wang H, et al. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats. *Am J Physiol Heart Circ Physiol*. 2015 Oct;309(7):H1130-40.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA